Abbott Laboratories
ABTAbbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including pharmaceuticals, diagnostic tools, medical devices, and nutritional products. Founded in 1888, Abbott is known for innovative solutions in medical diagnostics, cardiovascular and neurology devices, and nutrition, serving patients and healthcare providers worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| November 17, 2025 | $0.59 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $0.59 | 2025-07-15 | 2025-07-15 |
| May 15, 2025 | $0.59 | 2025-04-15 | 2025-04-15 |
| February 14, 2025 | $0.59 | 2025-01-15 | 2025-01-15 |
| November 15, 2024 | $0.55 | 2024-10-15 | 2024-10-15 |
Dividends Summary
- Abbott Laboratories has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 4 days ago, on November 17, 2025
- The highest dividend payed out to investors during this period was $0.59 per share
- The average dividend paid during this period was $0.36 per share.
Company News
The article highlights two healthcare stocks in the medical device and diabetes care market: DexCom and Abbott Laboratories. Both companies show strong financial performance and growth potential in the expanding global diabetes care market.
Law firm Monteverde & Associates is investigating the proposed sale of Exact Sciences to Abbott Laboratories, where shareholders are expected to receive $105.00 per common share.
Kuick Research released a comprehensive study on the US Orphan Drug Market, projecting market opportunities exceeding $190 billion by 2030, with over 850 orphan drugs in clinical trials and 500 marketed orphan drugs, highlighting significant investment potential in rare disease therapeutics.
Abbott Laboratories is well-positioned to withstand tariff impacts, with a diversified business and investments in domestic manufacturing facilities. The company's strong performance and positive analyst trends suggest it is on track to reach new highs in 2025.
Hims & Hers Health, Inc. (HIMS) has seen a 45.8% stock price increase in the past three months, outperforming the industry and broader market. The company's recent announcements, including the addition of GLP-1 injections to its weight loss portfolio and positive 2024 revenue outlook, have contributed to the stock's upward momentum.
